SEC Filing Summary: Hemispherx Biopharma, Inc. (10-K)
Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: A biopharmaceutical company focused on immune system-enhancing technologies. The company's primary assets are Ampligen (an experimental RNA drug for Chronic Fatigue Syndrome/ME/CFS and HIV) and Alferon N Injection (an FDA-approved natural alpha interferon for genital warts). The company also develops Alferon LDO (oral interferon) and Oragens.
Key Financial Metrics (Year Ended Dec 31, 2007)
| Metric | 2007 (in thousands) | 2006 (in thousands) |
|---|---|---|
| Total Revenues | $1,059 | $933 |
| Net Loss | $(18,139) | $(19,399) |
| Loss Per Share (Basic/Diluted) | $(0.25) | $(0.31) |
| Research & Development Expenses | $10,444 | $10,127 |
| General & Administrative Expenses | $8,974 | $8,225 |
| Cash & Cash Equivalents | $11,471 | $3,646 |
| Short-term Investments | $3,944 | $18,375 |
| Total Debt | $0 | $3,871 |
| Accumulated Deficit | $(185,190) | $(167,051) |
Note: The company reported no debt as of December 31, 2007, having retired all convertible debentures in June 2007.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13.5% to $1.059 million. This was driven by a 23% increase in Alferon N Injection sales ($175,000 increase), partially offset by a 27% decline in Ampligen cost-recovery sales ($49,000 decrease).
- Reduced Net Loss: Net loss decreased by 6.5% ($1.26 million) compared to 2006. This improvement was primarily due to:
- Lower interest expense and financing costs ($863,000 decrease) following the retirement of convertible debentures.
- Higher interest and other income ($646,000 increase) from maturing marketable securities.
- A reversal of previously accrued liquidated damages ($346,000) related to prior filing delays.
- Debt Elimination: The company retired all remaining debt related to convertible debentures issued between 2003 and 2004. Approximately $2.64 million in new funds was used to retire the debt, with the balance covered by collateral.
- Impairment Charges: The company recorded $526,000 in impairment losses in 2007, including a $228,000 write-down of a water purification system and a $298,000 write-down of an intangible asset (royalty interest) due to insufficient inventory to realize its value.
Guidance, Outlook, and Risks
Regulatory Status (Ampligen):
- An NDA for Ampligen to treat ME/CFS was filed on October 10, 2007.
- On December 3, 2007, the FDA issued a "Refusal to File" (RTF) letter, deeming the application "not substantially complete."
- The company submitted a response addressing 14 questions. A February 2008 meeting with the FDA reduced the outstanding issues to five items.
- Outlook: Management cannot provide guidance on when the NDA will be accepted or approved.
Liquidity and Capital Resources:
- As of December 31, 2007, the company held approximately $15.4 million in cash and short-term investments.
- Management believes these funds are sufficient to meet operating requirements for the next 18 months, contingent on curtailing discretionary spending.
- Financing Agreement: A common stock purchase agreement with Fusion Capital allows for up to $50 million in funding. However, purchases are suspended if the stock price falls below $1.00. As of March 2008, the stock price was $0.85, halting further sales under this agreement.
Key Risks:
- Product Development: Ampligen remains investigational; failure to obtain FDA approval would materially adversely affect operations.
- Competition: Alferon N faces competition from recombinant interferons and topical treatments (e.g., Aldara, Veregen).
- Legal Proceedings: Pending arbitrations with Esteve (Spain/Portugal distribution) and Bioclones (South Africa marketing agreement termination).
- Key Personnel: Reliance on Dr. William A. Carter (CEO/Co-inventor of Ampligen); loss of his services could be material.
Investor Verification Checklist
- Ampligen NDA Status: Verify the current status of the five remaining FDA questions and the timeline for resubmission.
- Cash Burn Rate: Confirm if the $15.4 million cash balance remains sufficient given the suspension of the Fusion Capital financing line due to stock price being under $1.00.
- Alferon N Sales Trend: Monitor unit sales volume versus revenue, as 2007 revenue growth was driven by price increases while unit sales declined.
- Legal Contingencies: Review the potential financial impact of the arbitrations with Esteve and Bioclones.
- Patent Expirations: Note that key HIV treatment patents expired or are expiring (2006-2009), relying on Orphan Drug status for protection.